Key Financial’s MiNK Therapeutics INKT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$50 Hold
4
– – ﹤0.01% 1293
2026
Q2
$47 Hold
4
– – ﹤0.01% 1340
2026
Q1
$42 Hold
4
– – ﹤0.01% 1377
2025
Q4
$45 Hold
4
– – ﹤0.01% 1424
2025
Q3
$59 Hold
4
– – ﹤0.01% 1441
2025
Q2
$30 Buy
+4
New +$30 ﹤0.01% 1427
2025
Q1
– Sell
-4
Closed -$30 – 1399
2024
Q4
$30 Hold
4
– – ﹤0.01% 1375
2024
Q3
$32 Hold
4
– – ﹤0.01% 1345
2024
Q2
$41 Hold
4
– – ﹤0.01% 1328
2024
Q1
$39 Hold
4
– – ﹤0.01% 1303
2023
Q4
$46 Hold
4
– – ﹤0.01% 1307
2023
Q3
$47 Hold
4
– – ﹤0.01% 1331
2023
Q2
$90 Buy
+4
New +$80 ﹤0.01% 1366

Other funds holding INKT

Key Financial's INKT Position: Q3 2026 in Review

Key Financial held its MiNK Therapeutics (INKT) position steady in Q3 2026 at 4 shares worth $50. The position accounts for ﹤0.01% of the portfolio, ranked #1293.

Key Financial first reported a position in INKT in Q2 2023 and has held it in 13 quarters since. The position peaked at $90 in Q2 2023. 22 funds tracked by Wall St. Rank hold INKT as of Q3 2026.

  • Key Financial held 4 shares of MiNK Therapeutics worth $50 as of Q3 2026.
  • Key Financial left its MiNK Therapeutics share count unchanged in Q3 2026.
  • MiNK Therapeutics made up ﹤0.01% of Key Financial's portfolio in Q3 2026, its #1293 holding.
  • Key Financial first reported a position in MiNK Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • Key Financial's MiNK Therapeutics position peaked at $90 in Q2 2023.
  • 22 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q3 2026.

Based on Key Financial's 13F filing for Q3 2026, filed 2 Nov 2026.